Experimental neurotransplantation treatment for hereditary cerebellar ataxias

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F16%3A10325248" target="_blank" >RIV/00216208:11140/16:10325248 - isvavai.cz</a>

Výsledek na webu

<a href="http://cerebellumandataxias.biomedcentral.com/articles/10.1186/s40673-016-0045-3" target="_blank" >http://cerebellumandataxias.biomedcentral.com/articles/10.1186/s40673-016-0045-3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s40673-016-0045-3" target="_blank" >10.1186/s40673-016-0045-3</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Experimental neurotransplantation treatment for hereditary cerebellar ataxias

Popis výsledku v původním jazyce

Hereditary cerebellar degenerations are a heterogeneous group of diseases often having a detrimental impact on patients' quality of life. Unfortunately, no sufficiently effective causal therapy is available for human patients at present. There are several therapies that have been shown to affect the pathogenetic process and thereby to delay the progress of the disease in mouse models of cerebellar ataxias. The second experimental therapeutic approach for hereditary cerebellar ataxias is neurotransplantation. Grafted cells might provide an effect via delivery of a scarce neurotransmitter, substitution of lost cells if functionally integrated and rescue or trophic support of degenerating cells. The results of cerebellar transplantation research over the past 30 years are reviewed here and potential benefits and limitations of neurotransplantation therapy are discussed.

Název v anglickém jazyce

Experimental neurotransplantation treatment for hereditary cerebellar ataxias

Popis výsledku anglicky

Hereditary cerebellar degenerations are a heterogeneous group of diseases often having a detrimental impact on patients' quality of life. Unfortunately, no sufficiently effective causal therapy is available for human patients at present. There are several therapies that have been shown to affect the pathogenetic process and thereby to delay the progress of the disease in mouse models of cerebellar ataxias. The second experimental therapeutic approach for hereditary cerebellar ataxias is neurotransplantation. Grafted cells might provide an effect via delivery of a scarce neurotransmitter, substitution of lost cells if functionally integrated and rescue or trophic support of degenerating cells. The results of cerebellar transplantation research over the past 30 years are reviewed here and potential benefits and limitations of neurotransplantation therapy are discussed.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

<a href="/cs/project/LO1503" target="_blank" >LO1503: BIOMEDIC</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cerebellum &amp; Ataxias

ISSN

2053-8871

e-ISSN

—

Svazek periodika

neuveden

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—